This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brugada, P. Articles by Wellens, H. J. Search for Related Content PubMed PubMed Citation Articles by Brugada, P. Articles by Wellens, H. J.

Circulation, Vol 79, 475-482, Copyright © 1989 by American Heart Association

ARTICLES

Transcoronary chemical ablation of ventricular tachycardia

P Brugada, H de Swart, JL Smeets and HJ Wellens
Department of Cardiology, University of Limburg, Academic Hospital, Maastricht, The Netherlands.

After identification of the artery supplying blood to the arrhythmogenic area, transcoronary chemical ablation of ventricular tachycardia was undertaken in three patients with incessant tachycardia in whom the other therapeutic options had failed. Sterile ethanol (96%) was given at a dose of 1.5 ml in two patients and a total of 6 ml in the third. The arrhythmia was cured in two patients and suppressed during a 1-month period in the third until new collateral blood supply to the arrhythmogenic area developed and ventricular tachycardia recurred. The procedure was then repeated successfully. After administration of ethanol in the high interventricular septum, one patient developed temporary complete atrioventricular block and a pacemaker was implanted. No other complications occurred. We observed that in patients with ventricular tachycardia after myocardial infarction, it is possible to identify and catheterize small coronary arteries responsible for blood supply to the site of origin or pathway of ventricular tachycardia. After careful transcoronary mapping with saline, chemical ablation can prevent further episodes of the arrhythmia in selected patients.

This article has been cited by other articles:

				E. M. Aliot, W. G. Stevenson, J. M. Almendral-Garrote, F. Bogun, C. H. Calkins, E. Delacretaz, P. D. Bella, G. Hindricks, P. Jais, M. E. Josephson, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA) Europace, June 1, 2009; 11(6): 771 - 817. [Full Text] [PDF]

				A L Baggish, R N Smith, I Palacios, G J Vlahakes, D M Yoerger, M H Picard, P A Lowry, I-k Jang, and M A Fifer Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy Heart, December 1, 2006; 92(12): 1773 - 1778. [Abstract] [Full Text] [PDF]

				P. J. Wang Rate Control: Is Local Better? Circulation, May 23, 2006; 113(20): 2374 - 2376. [Full Text] [PDF]

				J. Brugada, A. Berruezo, A. Cuesta, J. Osca, E. Chueca, X. Fosch, L. Wayar, and L. Mont Nonsurgical transthoracic epicardial radiofrequency ablation: An alternative in incessant ventricular tachycardia J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2036 - 2043. [Abstract] [Full Text] [PDF]

				E. Sosa, M. Scanavacca, A. d'Avila, F. Oliveira, and J. A. F. Ramires Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1442 - 1449. [Abstract] [Full Text] [PDF]

				L Faber, A Meissner, P Ziemssen, and H Seggewiss Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients Heart, March 1, 2000; 83(3): 326 - 331. [Abstract] [Full Text]

				H. Kuhn, F.H. Gietzen, M. Schafers, M. Freick, B. Gockel, C. Strunk-Muller, E. Jachmann, and O. Schober Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion Eur. Heart J., December 2, 1999; 20(24): 1808 - 1817. [Abstract] [PDF]

				J. S. Steinberg, A. Gaur, R. Sciacca, and E. Tan New-Onset Sustained Ventricular Tachycardia After Cardiac Surgery Circulation, February 23, 1999; 99(7): 903 - 908. [Abstract] [Full Text] [PDF]

				L. Faber, H. Seggewiss, and U. Gleichmann Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy : Results With Respect to Intraprocedural Myocardial Contrast Echocardiography Circulation, December 1, 1998; 98(22): 2415 - 2421. [Abstract] [Full Text] [PDF]

				A. A V de Paola, W. D S Melo, M. Z P Tavora, and E. E Martinez Angiographic and electrophysiological substrates for ventricular tachycardia mapping through the coronary veins Heart, January 1, 1998; 79(1): 59 - 63. [Abstract] [Full Text] [PDF]

				TRANSCORONARY ABLATION STOPS VENTRICULAR TACHYCARDIA Journal Watch (General), March 21, 1989; 1989(321): 9 - 9. [Full Text]